Sight Sciences (NASDAQ:SGHT) Given New $5.00 Price Target at Stifel Nicolaus

Sight Sciences (NASDAQ:SGHT) had its target price trimmed by Stifel Nicolaus from $6.00 to $5.00 in a report issued on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

SGHT has been the topic of a number of other reports. Piper Sandler reissued a “neutral” rating and issued a $5.50 price objective (down from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research report on Tuesday, January 14th. Morgan Stanley lowered their price objective on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Monday, November 11th. Lake Street Capital cut their target price on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a research note on Wednesday, January 15th. Finally, Citigroup decreased their price target on shares of Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Sight Sciences presently has an average rating of “Hold” and a consensus price target of $4.68.

Sight Sciences Stock Performance

Shares of NASDAQ:SGHT opened at $2.71 on Thursday. Sight Sciences has a 52 week low of $2.67 and a 52 week high of $8.45. The firm’s fifty day moving average is $3.36 and its 200-day moving average is $5.01. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The company had revenue of $20.16 million for the quarter, compared to analyst estimates of $20.41 million. Research analysts forecast that Sight Sciences will post -1 EPS for the current fiscal year.

Insider Buying and Selling at Sight Sciences

In related news, CEO Paul Badawi sold 24,819 shares of Sight Sciences stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $2.92, for a total transaction of $72,471.48. Following the transaction, the chief executive officer now owns 5,676,331 shares of the company’s stock, valued at $16,574,886.52. The trade was a 0.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders purchased 15,000 shares of company stock worth $58,232 and sold 63,014 shares worth $197,295. Company insiders own 28.90% of the company’s stock.

Institutional Investors Weigh In On Sight Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of SGHT. KCK LTD. bought a new stake in shares of Sight Sciences in the 4th quarter worth $15,925,000. Geode Capital Management LLC grew its position in Sight Sciences by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after purchasing an additional 12,709 shares in the last quarter. State Street Corp grew its position in Sight Sciences by 17.4% in the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock worth $4,075,000 after purchasing an additional 95,843 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Sight Sciences by 4.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 268,250 shares of the company’s stock valued at $976,000 after buying an additional 11,259 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Sight Sciences by 46.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock worth $1,310,000 after buying an additional 65,767 shares in the last quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.